Exelixis Inc. Common Stock vs Johnson Controls International PLC — how do they compare? Exelixis Inc. Common Stock trades at $59.86 (market cap $14.62B), while Johnson Controls International PLC trades at $157.44 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 6.4× Exelixis Inc. Common Stock's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Exelixis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 1 Days and Johnson Controls International PLC for 65 Days on average.
| EXEL | JCI | |
|---|---|---|
Market Cap | $14.62B | $93.28B |
Volume | 2,684,957 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $59.86 | $158.76 |
52-Week Low | $34.54 | $105.55 |
Typical Hold Time | 1 Days | 65 Days |
Enterprise Value | $13.95B | $102.12B |
Dividend Yield | — | 1.04% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Johnson Controls (JCI) trades at $154.00, down 1.24% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q3 2026 EPS of $1.42 beating expectations by 9.2% and raising full-year guidance. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong demand for data-center thermal management systems and inclusion in AI industrial stock recommendations.
JCI presents a compelling investment case with 62% analyst buy ratings and $172.50 consensus price target offering 12% upside. The company benefits from strong AI-driven demand in thermal management systems, though elevated P/E of 43.38 and debt-to-asset ratio increasing to 26.06% warrant monitoring. Execution on raised FY26 guidance and data-center market expansion remain key catalysts for continued growth.
Trailing returns across standard periods
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →